124
Participants
Start Date
February 28, 2006
Primary Completion Date
August 31, 2007
Study Completion Date
June 30, 2008
dorzolamide-timolol-brimonidine
Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
Instituto de la Visión. Hospital Universitario La Carlota. Universidad de Montemorelos, Montemorelos
Laboratorios Sophia S.A de C.V.
INDUSTRY